Log in with your email address username.

×

Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Correspondence] Bivalirudin versus heparin use for patients undergoing PPCI

Adeel Shahzad and colleagues1 concluded that heparin, compared with bivalirudin, reduces the incidence of major adverse cardiovascular events (MACEs) in a setting of primary percutaneous coronary intervention without increasing the risk of bleeding complications. However, findings from this study1 do not accord with those from other multicentre randomised trials.2,3 In the study by Shahzad and colleagues,1 the incidence of overall MACE rates in the bivalirudin group was very high compared with other studies, but the rates reported between the other studies were comparable (table).

email